A comprehensive analysis of 559 oesophageal and gastric cancer samples, collected from patients around the world, suggests the two main types of oesophageal cancer differ markedly in their molecular characteristics and should be considered separate diseases.
The study, published today in Nature from The Cancer Genome Atlas (TCGA) Research Network, includes two key takeaways.
First, upper oesophageal cancers more closely resemble cancers of the head and neck, while tumours further down in the oesophagus are virtually indistinguishable from a subtype of stomach cancer.
Second, cancer clinical trials should group patients according to molecular subtype--in general, grouping lower oesophageal tumours with stomach cancers, while evaluating upper oesophageal cancers separately.
"These findings add several layers of depth and sophistication to our current understanding of oesophageal cancer genomics," said Adam Bass, M.D., co-leader of TCGA's oesophageal cancer study and physician-scientist at Dana-Farber Cancer Institute. "Our hope is this work settles several long-standing uncertainties in the oesophageal cancer field and will serve as the definitive reference manual for researchers and drug developers seeking more effective clinical trials and new treatment approaches."
Physicians have known for decades that oesophageal cancers, when looked at under the microscope, fall into one of two categories--adenocarcinomas, which resemble stomach or colorectal cancers, and squamous cell carcinomas, which are similar to some lung, skin, and head and neck cancers.
What remained unknown was the extent to which adenocarcinomas and squamous oesophageal cancers differ molecularly and the relationship between oesophageal adenocarcinoma and stomach adenocarcinoma.
"We have shown that these clinical subtypes differ profoundly at the molecular level," said Peter W. Laird, Ph.D., a principal investigator in the international TCGA Research Network and a professor at Van Andel Research Institute. "These findings suggest that whether the tumour originates in the oesophagus or the stomach is less relevant than the molecular characteristics of the individual tumours."
Oesophageal cancer represents just 1 percent of new cancer diagnoses in the U.S. However, it kills 4-in-5 patients within five years of diagnosis, and current treatment approaches often fail to help.
Additionally, cases of oesophageal adenocarcinoma have skyrocketed over the last four decades, increasing seven-fold since the mid-1970s.
Within the field, there has been great uncertainty regarding the relationship between this growing burden of oesophageal adenocarcinoma and adenocarcinomas that occur in the stomach.
Results from this new report argue against the need to continue to debate the demarcations of oesophageal and gastric adenocarcinoma and instead view gastroesophageal adenocarcinoma as a more singular entity, analogous to colorectal cancer.
Specifically, this study revealed that oesophageal adenocarcinomas have striking molecular similarity to a class of stomach cancers called chromosomally unstable tumours, the hallmark of which are significant structural chromosomal aberrations.
Oncologists say this nuanced view of the disease, including the detailed molecular taxonomy of oesophageal adenocarcinomas, will likely change their approach to studies and treatment.
"It is clear from the TCGA data that oesophageal squamous and oesophageal adenocarcinomas are completely different diseases and should never be included in the same therapeutic trial," said Yelena Y. Janjigian, M.D., a gastrointestinal oncologist from Memorial Sloan Kettering Cancer Center who was not involved in the study. "In oesophageal adenocarcinoma, it is likely a combination of pathways and therapeutic strategies that will be successful. The therapeutic significance of these alterations will be explored in follow-up studies."
Members of the TCGA Research Network team say these studies represent the work of dedicated collaborators, who seek to maximise results in search of new ways to battle cancer.
"Studies from TCGA transcend the work of any one institution or individual," said Ilya Shmulevich, Ph.D., a principal investigator in the international TCGA Research Network and a professor at the Institute for Systems Biology. "These are massive undertakings that are possible only through contributions from hundreds of specialists and scientists around the world--people dedicate years of their lives to these projects in the hope of finding new treatments for people who are very sick."
Source: Van Andel Research Institute
(22 Feb 2017)
(22 Feb 2017)